Prabhudas Lilladher ne Sai Life Sciences par coverage shuru ki hai aur ₹1,620 ka target price diya hai. Company ka plan agle kuch saalon mein tezi se expand karne ka hai.
Naya Bullish Call!
Brokerage firm Prabhudas Lilladher ne Sai Life Sciences par apni bullish report release ki hai. Unhone stock par 'Buy' rating di hai aur ₹1,620 ka target set kiya hai. Brokerage ka kehna hai ki company ka 'Integrated CRDMO' model inhe drug development ke har stage par advantage deta hai, jo pharmaceutical giants ke liye ek bada attraction point hai.
Kya hai growth ka logic?
Analysts ne agle kuch saalon ke liye kaafi strong projections diye hain. Financial Year 2029 tak, revenue mein 21% aur net profit mein 26% ki compounded annual growth rate (CAGR) ki umeed hai. Is growth ko fuel karne ke liye management ne ₹11 billion se ₹13 billion ka bada capital expenditure plan banaya hai jo 2027 tak pura hona hai. Isse production capacity badhegi aur bade clients ke saath relations aur mazboot honge.
Risk par dhyan dena zaroori hai!
Sab kuch bullish nahi hai, execution risk par nazar rakhna padega. Itna bada capital spending company ki financial flexibility par dabav daal sakta hai. Returns is baat par depend karenge ki company kitne high-value projects la pati hai aur apni facility utilization ko kaise maintain karti hai.
Regulatory hurdles bhi ek bada factor hain, kyunki pharma sector mein global health authorities ka inspection kabhi bhi mushkil paida kar sakta hai. Valuation ke hisaab se stock 55x earnings par trade kar raha hai, jo iski premium growth expectations ko reflect karta hai. Investors ko ab bas yeh dekhna hai ki expansion projects kitni speed se aage badhte hain.